Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) has completed the acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland, and a warehousing center in Frederick, Maryland, for $122.5 million. The transaction, conducted through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO service agreement with MacroGenics.
With this acquisition, Bora Biologics, the biologics CDMO franchise of Bora Group, now operates 20,000 liters of single-use bioreactor drug substance manufacturing capacity across two active US sites: Rockville, Maryland, and San Diego, California, along with a development facility in Zhubei, Taiwan. This expansion positions Bora as a key player in the US biologics contract manufacturing market.
Bobby Sheng, Chairman and CEO of Bora Group, emphasized the strategic importance of the acquisition: "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply. As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure."
The Rockville facility adds to Bora Biologics' capabilities, which now support more than four active commercial programs and over 120 completed GMP batches. These batches supply multiple global markets, including the US, EU, Japan, Canada, and the UK, with fully integrated quality control and analytical capabilities.
Bora Biologics' US network has undergone five FDA inspections, including two at Rockville and one PMDA review in 2025, all with clean results. The combined platform has supported more than 33 biologics and 15 biosimilars, offering a manufacturing base that reduces offshore dependency by providing domestically anchored infrastructure.
Looking ahead, Bora Group plans to integrate its US drug substance capabilities with existing sterile drug product capabilities over the next 12 to 18 months, aiming to provide a seamless, fully integrated development-through-commercial biologics solution. This integration is expected to enhance efficiency and reliability for clients seeking end-to-end services.
For more information about Bora Pharmaceuticals and its CDMO services, visit https://www.bora-corp.com or https://www.boracdmo.com.
